Creo Medical Group PLC's (AIM:CREO) main product is called speedboat which is a cutting and coagulation device that goes at the end of an endoscope mainly for surgery in the bowel to remove cancerous and pre-cancerous lesions.
Core or non-distribution sales are expected to be very high over the next few years Savin says, and are currently doubling quarter on quarter.
It is such a large market to go for and with these high growth rates and a strong IP position, Creo is very well-placed Savin says.